Dr. De Alba will discuss preclinical studies that show the potential of the Company’s lead clinical asset, ‘1104, for treating atopic dermatitis (AD). In a chronic allergen-driven murine model of AD, ...
The MarketWatch News Department was not involved in the creation of this content. GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited ...
NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior ...
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced its decision to accelerate the advancement of a sublingual, ...
In multiple preclinical models evaluated in single-dose toxicity studies, there were no ‘1104-related local tolerability adverse effects after treatment with the ‘1104 SQ formulation at dose levels ...
NEW ORLEANS and CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve ...
Revolo completes patient enrollment in phase 2 trial of ‘1104 in eosinophilic esophagitis: New Orleans Wednesday, September 14, 2022, 14:30 Hrs [IST] Revolo Biotherapeutics (Rev ...
Data continues to differentiate '1104 as a potential allergic disease treatment that acts upstream in the immune cascade '1104 reduces key indices of skin inflammation and inflammatory mediators in a ...
‘1104 has previously shown an efficacy signal in a Phase 2 clinical study of eosinophilic esophagitis and preclinical allergic inflammation models. Dr. De Alba will discuss how ‘1104 has now shown ...
In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of '1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models ...
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited ("Revolo”) today announced that it will present a poster on its lead candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results